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COUNTERFEIT PHARMACEUTICALS: AN INTRODUCTION
Michael S. Mireles1
In February 2008, the Wake Forest University Intellectual Property
Law Journal sponsored a symposium titled Counterfeit
Pharmaceuticals.2 The symposium brought together academics and
practitioners to explore issues involving combating the supply of and
controlling the demand for counterfeit pharmaceuticals and to
recommend policy solutions to those issues. This symposium is
particularly timely given recent issues concerning access to affordable
pharmaceuticals, the use of internet pharmacies, and the tragic deaths
of patients who used counterfeit drugs in developing countries as well
as numerous reports of adulterated or fake drugs entering the United
States and other developed countries. The contributions made in this
symposium provide a productive step toward creating practical
solutions to the complex issues involving counterfeit pharmaceuticals.
The symposium included a keynote presentation by Professor Bryan
A. Liang, the Executive Director and Professor of Law at the Institute
of Health Law Studies, California Western School of Law, and
presentations by William K. Hubbard, the Former Senior Associate
Commissioner for Policy, Planning, and Legislation of the Food and
Drug Administration; Jake Wharton, an associate at Womble Carlyle;
James Thomas, partner at Troutman Sanders and Former Vice
President and Trademark Counsel for GlaxoSmithKline; and Professor
Sandra L Rierson, an Assistant Professor of Law and Director of the
Center for Law, Technology and Communications at Thomas
Jefferson School of Law. This symposium issue of the Wake Forest
University Intellectual Property Law Journal is dedicated to
addressing issues concerning counterfeit pharmaceuticals and includes
papers by Professor Liang; Professor Robert C. Bird, an Assistant
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Associate Professor, University of the Pacific, McGeorge School of Law.
The symposium website is at http://ipjournal.law.wfu.edu/symposium.
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Professor at the School of Business, Department of Marketing and
Law, University of Connecticut; Professor Daniel Cahoy, an Associate
Professor of Business Law at the Smeal College of Business,
Pennsylvania State University; and Professor Rierson.
Professor Bryan A. Liang provides an extensive analysis of problems
related to the access of authentic pharmaceuticals and the availability
of pharmaceuticals at affordable prices in his article, A Dose of
Reality: Promoting Access to Pharmaceuticals. Through this
framework, Professor Liang identifies root causes for the counterfeit
pharmaceutical crisis and proposes a legislative solution that attempts
to address issues concerning the price of and access to authentic
pharmaceuticals. The proposal includes a low cost/no cost drug
program for certain patients along with the identification and
registration of wholesalers. The proposal also provides for a ban of
Internet pharmaceutical sales without proper accreditation, the
prohibition of drug importation, a public and provider education
program concerning pharmaceutical drugs, and increased criminal
penalties for counterfeiters.
Professor Bird asserts that an examination of consumer demand for
counterfeit pharmaceuticals has been under-analyzed in legal literature
and examines marketing literature concerning consumer behavior and
counterfeit pharmaceuticals in Counterfeit Drugs: The Global
Consumer Perspective. Professor Bird proposes that pharmaceutical
companies can use lessons from marketing literature to effectively
tailor messages to consumers to direct them to purchase genuine
pharmaceuticals instead of counterfeits, and thus reduce the demand
for counterfeits.
Professor Daniel Cahoy, in Addressing the North-South Divide in
Pharmaceutical Counterfeiting, analyzes the division between the
developed and developing worlds and how differences between the
two inform the creation of solutions to safety issues raised by
counterfeit pharmaceuticals in developing countries. He proposes that
policy makers provide positive and negative incentives for private
industry to combat pharmaceutical counterfeiting in developing
countries. Some of those incentives include tort liability for not using
technology to stop counterfeiting, increased awareness of the
counterfeiting of pharmaceuticals to create distrust in the minds of
consumers leading to loss of market share and shame, and direct
rewards for anti-counterfeiting initiatives such as subsidies.
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Finally, In Pharmaceutical Counterfeiting and the Puzzle of Remedies,
Professor Sandra L. Rierson examines the remedies provided for
counterfeiting pharmaceuticals and other goods, and argues that the
law both overpenalizes some types of counterfeiting and
underpenalizes other forms of counterfeiting. She proposes that legal
remedies for counterfeiting should take into account the amount of
moral culpability and the actual harm resulting from counterfeiting,
and should provide federal remedies not only to trademark holders, but
also end-consumers.
Thank you to all of the participants, presenters, and contributors in the
Counterfeit Pharmaceuticals symposium and this symposium issue of
the Wake Forest Intellectual Property Law Journal.

